Explicyte Immuno-Oncology - Cancer Immunotherapy CRO Services
Cancer Immunotherapy CRO Services
In vitro
Tumor killing
Tumor sensitization
Activation & immune checkpoint inhibition
Antibody-dependent cell cytotoxicity (ADCC)
Tumor antigen-specific killing
Immuno-modulation
Immune cell activation
Immune cell migration
Mixed lymphocyte reaction (MLR)
Macrophage assays
TLS-GC reaction
Cytokine release syndrome
In Vivo
Responsiveness to immunotherapies
PD-1/PD-L1 axis blockade
CTLA-4 blockade
Immunization
Syngeneic tumor models
Breast Cancer : 4T1
Breast Cancer : EMT6
Colon Cancer : CT26
Colon Cancer : MC38
Glioblastoma : GL261
Lung Cancer : Lewis LLC1
Pancreatic Cancer : Pan02
Renal Cancer : Renca
Sarcoma : MCA-205
Translational
Services
Custom tumor tissue sourcing
Target validation
Preclinical immune profiling
Biomarker discovery & testing
Image analysis
Technological platforms
Quantitative digital pathology
Digital spatial profiling
Single-cell spatial transcriptomics
Single-cell RNA Seq
Proteomics
Flow cytometry
Featured service
TLS detection & evaluation
Spatial transcriptomics
Single-cell analysis
Spatial biology
About
About Explicyte
Science
News
Careers
Contact us
Toggle menu
Contact us
CRO Services
Explicyte Immuno-Oncology
>
CRO Services
View Details
Target identification & validation for cancer immunotherapies
View Details
Quantitative digital pathology
View Details
Sarcoma
View Details
Renal Cancer
View Details
Glioma
View Details
Colon cancer
View Details
Colon Cancer
View Details
Triple Negative Breast Cancer
View Details
Breast Cancer
View Details
Immune cell tumor killing
View Details
Antibody-dependent cell cytotoxicity (ADCC)
View Details
Macrophage assays
Previous page
1
2
3
4
Next page
WordPress Lightbox
